Antipsychotic  ||| S:0 E:14 ||| JJ
long-acting  ||| S:14 E:26 ||| JJ
injections ||| S:26 E:36 ||| NNS
:  ||| S:36 E:38 ||| :
prescribing  ||| S:38 E:50 ||| JJ
practice  ||| S:50 E:59 ||| NN
in  ||| S:59 E:62 ||| IN
the  ||| S:62 E:66 ||| DT
UK  ||| S:66 E:69 ||| NNP
Data  ||| S:69 E:74 ||| NNP
from  ||| S:74 E:79 ||| IN
the  ||| S:79 E:83 ||| DT
USA ||| S:83 E:86 ||| NNP
,  ||| S:86 E:88 ||| ,
Australia  ||| S:88 E:98 ||| NNP
and  ||| S:98 E:102 ||| CC
Europe  ||| S:102 E:109 ||| NNP
suggest  ||| S:109 E:117 ||| VBP
that  ||| S:117 E:122 ||| IN
the  ||| S:122 E:126 ||| DT
proportion  ||| S:126 E:137 ||| NN
of  ||| S:137 E:140 ||| IN
patients  ||| S:140 E:149 ||| NNS
with  ||| S:149 E:154 ||| IN
schizophrenia  ||| S:154 E:168 ||| NN
prescribed  ||| S:168 E:179 ||| VBN
an  ||| S:179 E:182 ||| DT
antipsychotic  ||| S:182 E:196 ||| JJ
long-acting  ||| S:196 E:208 ||| JJ
injection  ||| S:208 E:218 ||| NN
( ||| S:218 E:219 ||| -LRB-
LAI ||| S:219 E:222 ||| NNP
)  ||| S:222 E:224 ||| -RRB-
varies  ||| S:224 E:231 ||| VBZ
from  ||| S:231 E:236 ||| IN
around  ||| S:236 E:243 ||| IN
a  ||| S:243 E:245 ||| DT
quarter  ||| S:245 E:253 ||| NN
to  ||| S:253 E:256 ||| TO
a  ||| S:256 E:258 ||| DT
third ||| S:258 E:263 ||| JJ
.  ||| S:263 E:265 ||| .
Use  ||| S:265 E:269 ||| NN
of  ||| S:269 E:272 ||| IN
LAIs  ||| S:272 E:277 ||| NNP
has  ||| S:277 E:281 ||| VBZ
been  ||| S:281 E:286 ||| VBN
associated  ||| S:286 E:297 ||| VBN
with  ||| S:297 E:302 ||| IN
male  ||| S:302 E:307 ||| JJ
gender  ||| S:307 E:314 ||| NN
and  ||| S:314 E:318 ||| CC
younger  ||| S:318 E:326 ||| JJR
age ||| S:326 E:329 ||| NN
.  ||| S:329 E:331 ||| .
To  ||| S:331 E:334 ||| TO
characterise  ||| S:334 E:347 ||| VB
the  ||| S:347 E:351 ||| DT
use  ||| S:351 E:355 ||| NN
of  ||| S:355 E:358 ||| IN
LAIs  ||| S:358 E:363 ||| JJ
in  ||| S:363 E:366 ||| IN
people  ||| S:366 E:373 ||| NNS
with  ||| S:373 E:378 ||| IN
schizophrenia  ||| S:378 E:392 ||| NN
in  ||| S:392 E:395 ||| IN
three  ||| S:395 E:401 ||| CD
clinical  ||| S:401 E:410 ||| JJ
settings  ||| S:410 E:419 ||| NNS
in  ||| S:419 E:422 ||| IN
the  ||| S:422 E:426 ||| DT
UK ||| S:426 E:428 ||| NNP
.  ||| S:428 E:430 ||| .
The  ||| S:430 E:434 ||| DT
study  ||| S:434 E:440 ||| NN
used  ||| S:440 E:445 ||| VBN
audit  ||| S:445 E:451 ||| NN
data  ||| S:451 E:456 ||| NNS
from  ||| S:456 E:461 ||| IN
quality  ||| S:461 E:469 ||| NN
improvement  ||| S:469 E:481 ||| NN
programmes  ||| S:481 E:492 ||| VBZ
conducted  ||| S:492 E:502 ||| VBN
by  ||| S:502 E:505 ||| IN
the  ||| S:505 E:509 ||| DT
Prescribing  ||| S:509 E:521 ||| NNP
Observatory  ||| S:521 E:533 ||| NNP
for  ||| S:533 E:537 ||| IN
Mental  ||| S:537 E:544 ||| NNP
Health ||| S:544 E:550 ||| NNP
.  ||| S:550 E:552 ||| .
Long-acting  ||| S:552 E:564 ||| JJ
injections  ||| S:564 E:575 ||| NNS
were  ||| S:575 E:580 ||| VBD
found  ||| S:580 E:586 ||| VBN
to  ||| S:586 E:589 ||| TO
be  ||| S:589 E:592 ||| VB
prescribed  ||| S:592 E:603 ||| VBN
for  ||| S:603 E:607 ||| IN
between  ||| S:607 E:615 ||| IN
a  ||| S:615 E:617 ||| DT
quarter  ||| S:617 E:625 ||| NN
and  ||| S:625 E:629 ||| CC
a  ||| S:629 E:631 ||| DT
third  ||| S:631 E:637 ||| JJ
of  ||| S:637 E:640 ||| IN
patients ||| S:640 E:648 ||| NNS
,  ||| S:648 E:650 ||| ,
depending  ||| S:650 E:660 ||| VBG
on  ||| S:660 E:663 ||| IN
the  ||| S:663 E:667 ||| DT
clinical  ||| S:667 E:676 ||| JJ
setting ||| S:676 E:683 ||| NN
.  ||| S:683 E:685 ||| .
Flupentixol ||| S:685 E:696 ||| NNP
,  ||| S:696 E:698 ||| ,
risperidone  ||| S:698 E:710 ||| NN
and  ||| S:710 E:714 ||| CC
zuclopenthixol  ||| S:714 E:729 ||| NNS
were  ||| S:729 E:734 ||| VBD
most  ||| S:734 E:739 ||| RBS
commonly  ||| S:739 E:748 ||| RB
prescribed  ||| S:748 E:759 ||| VBN
and  ||| S:759 E:763 ||| CC
were  ||| S:763 E:768 ||| VBD
combined  ||| S:768 E:777 ||| VBN
with  ||| S:777 E:782 ||| IN
an  ||| S:782 E:785 ||| DT
oral  ||| S:785 E:790 ||| JJ
antipsychotic  ||| S:790 E:804 ||| NN
in  ||| S:804 E:807 ||| IN
half  ||| S:807 E:812 ||| NN
of  ||| S:812 E:815 ||| IN
cases ||| S:815 E:820 ||| NNS
,  ||| S:820 E:822 ||| ,
frequently  ||| S:822 E:833 ||| RB
constituting  ||| S:833 E:846 ||| JJ
high-dose  ||| S:846 E:856 ||| JJ
prescribing ||| S:856 E:867 ||| NN
.  ||| S:867 E:869 ||| .
The  ||| S:869 E:873 ||| DT
use  ||| S:873 E:877 ||| NN
of  ||| S:877 E:880 ||| IN
LAIs  ||| S:880 E:885 ||| NNP
was  ||| S:885 E:889 ||| VBD
not  ||| S:889 E:893 ||| RB
consistently  ||| S:893 E:906 ||| RB
associated  ||| S:906 E:917 ||| VBN
with  ||| S:917 E:922 ||| IN
age ||| S:922 E:925 ||| NN
,  ||| S:925 E:927 ||| ,
gender  ||| S:927 E:934 ||| NN
or  ||| S:934 E:937 ||| CC
ethnicity ||| S:937 E:946 ||| NN
.  ||| S:946 E:948 ||| .
Antipsychotic  ||| S:948 E:962 ||| JJ
LAIs  ||| S:962 E:967 ||| NNS
are  ||| S:967 E:971 ||| VBP
commonly  ||| S:971 E:980 ||| RB
prescribed ||| S:980 E:990 ||| VBN
.  ||| S:990 E:992 ||| .
We  ||| S:992 E:995 ||| PRP
did  ||| S:995 E:999 ||| VBD
not  ||| S:999 E:1003 ||| RB
replicate  ||| S:1003 E:1013 ||| VB
previous  ||| S:1013 E:1022 ||| JJ
findings  ||| S:1022 E:1031 ||| NNS
with  ||| S:1031 E:1036 ||| IN
respect  ||| S:1036 E:1044 ||| NN
to  ||| S:1044 E:1047 ||| TO
demographic  ||| S:1047 E:1059 ||| JJ
variables  ||| S:1059 E:1069 ||| NNS
associated  ||| S:1069 E:1080 ||| VBN
with  ||| S:1080 E:1085 ||| IN
their  ||| S:1085 E:1091 ||| PRP$
use ||| S:1091 E:1094 ||| NN
.  ||| S:1094 E:1096 ||| .
